Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Disruption of the p53-Mdm2 complex by Nutlin-3 reveals different cancer cell phenotypes.

Ethnicity & disease - 1 Jan 2008

Arva Nicoleta C, Talbott Kathryn E, Okoro Danielle R, Brekman Angelika, Qiu Wei Gang, Bargonetti Jill

Abstract excerpt

INTRODUCTION: Mdm2 inhibits p53 transactivation by forming a p53-Mdm2 complex on chromatin. Upon DNA damage-induced complex disruption, such latent p53 can be activated, but in cells overexpressing Mdm2 because of a homozygous single nucleotide polymorphism at position 309 (T --> G) of mdm2, the complex is highly stable and cannot be disrupted by DNA damage, rendering p53 inactive. METHODS: To determine whether...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to DNA Damage

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Etoposide

Share to Flow Cytometry

Share to Imidazoles

Share to Piperazines

Share to Proto-Oncogene Proteins c-mdm2

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 18646312
PMCID: PMC3535287

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Disruption of the p53-Mdm2 complex by Nutlin-3 reveals different cancer cell phenotypes.PMID 18646312Read ↗

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapySemantic proximity Read ↗

Homozygous mdm2 SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death.Semantic proximity Read ↗

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.Semantic proximity Read ↗

Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.Semantic proximity Read ↗

Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer CellsSemantic proximity Read ↗

A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells.Semantic proximity Read ↗

Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradationSemantic proximity Read ↗

Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes.Semantic proximity Read ↗

Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?Semantic proximity Read ↗

Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3.Semantic proximity Read ↗

MDM2-p53 Interactions in Human Hepatocellular Carcinoma: What Is the Role of Nutlins and New Therapeutic Options?Semantic proximity Read ↗

Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.